THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: Form 990, tax year 2025

View the entire original 990 at ProPublica ↗

Organization
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (EIN 06-1504413)
Tax period
2025-01-01 to 2025-12-31
Filed
2026-08-25
IRS object ID
202632379349301803
Schema version
2025v4.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2026-08-25T15:29:58-05:00ReturnTs
Tax Period End2025-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN331374517PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1PKF O'CONNOR DAVIES ADVISORY LLCBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line13001 SUMMER STREET 5TH FLOOR EASTAddressLine1Txt
CitySTAMFORDCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06905ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2025-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN061504413EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE MULTIPLE MYELOMA RESEARCHBusinessNameLine1Txt
Business Name Line2FOUNDATION INCBusinessNameLine2Txt
FieldValueIRS element (for citing)
Business Name ControlMULTBusinessNameControlTxt
Phone2032290464PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVENUE 7TH FLAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonMICHAEL ANDREINIPersonNm
Person TitlePRESIDENT & CEOPersonTitleTxt
Phone2032290464PhoneNum
Signature2026-08-25SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonMELISSA MODELSONPreparerPersonNm
PTINP01603524PTIN
Phone2033232400PhoneNum
Preparation2026-08-25PreparationDt
FieldValueIRS element (for citing)
Tax2025TaxYr
Build TS2025-03-06 01:10:19ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerMICHAEL ANDREINIPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVENUE 7TH FLAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$120,070,404GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.THEMMRF.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1998FormationYr
Legal Domicile StateCTLegalDomicileStateCd
Activity Or MissionSEE SCHEDULE OActivityOrMissionDesc
Voting Members Governing Body14VotingMembersGoverningBodyCnt
Voting Members Independent14VotingMembersIndependentCnt
Total Employee80TotalEmployeeCnt
Total Volunteers200TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$24,100,727PYContributionsGrantsAmt
CY Contributions Grants$26,628,081CYContributionsGrantsAmt
PY Program Service Revenue$2,261,716PYProgramServiceRevenueAmt
CY Program Service Revenue$8,674,361CYProgramServiceRevenueAmt
PY Investment Income$2,238,351PYInvestmentIncomeAmt
CY Investment Income$1,150,050CYInvestmentIncomeAmt
PY Other Revenue$500,620PYOtherRevenueAmt
CY Other Revenue$70,864CYOtherRevenueAmt
PY Total Revenue$29,101,414PYTotalRevenueAmt
CY Total Revenue$36,523,356CYTotalRevenueAmt
PY Grants And Similar Paid$6,080,876PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$3,576,906CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$11,390,435PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$12,331,616CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$6,107,004CYTotalFundraisingExpenseAmt
PY Other Expenses$18,133,026PYOtherExpensesAmt
CY Other Expenses$18,742,609CYOtherExpensesAmt
PY Total Expenses$35,604,337PYTotalExpensesAmt
CY Total Expenses$34,651,131CYTotalExpensesAmt
PY Revenues Less Expenses-$6,502,923PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$1,872,225CYRevenuesLessExpensesAmt
Total Assets BOY$66,397,148TotalAssetsBOYAmt
Total Assets EOY$62,872,951TotalAssetsEOYAmt
Total Liabilities BOY$16,374,755TotalLiabilitiesBOYAmt
Total Liabilities EOY$14,844,396TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$50,022,393NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$48,028,555NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionSEE SCHEDULE OMissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$6,096,220ExpenseAmt
Grant$0GrantAmt
Revenue$8,674,361RevenueAmt
DescTHE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC), THE CLINICAL RESEARCH SUBSIDIARY OF THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF), IS A COLLABORATIVE NETWORK OF LEADING CANCER CENTERS DRIVING CUTTING-EDGE CLINICAL TRIALS. THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC TO DRIVE PROGRESS FOR PATIENTS WHO NEED IT MOST. HORIZON TRIALS USE AN ADAPTIVE PLATFORM DESIGN THAT ALLOWS RESEARCHERS TO TEST SEVERAL TREATMENTS AT THE SAME TIME AND ADD NEW OPTIONS AS DATA BECOMES AVAILABLE. IN 2025, THE HORIZON ONE TRIAL FOCUSED ON RELAPSED/REFRACTORY MYELOMA EXCEEDED MANY OF ITS ENROLLMENT GOALS FOR ITS FIRST TREATMENT ARM, WHICH IS TESTING DOSING APPROACHES FOR A BISPECIFIC ANTIBODY. THE TRIAL SO FAR HAS ENROLLED MORE BLACK PATIENTS AND OLDER ADULTSTWO GROUPS THAT HAVE HISTORICALLY BEEN LEFT OUT OF RESEARCHTHAN MOST MYELOMA TRIALS. HORIZON ONE BECAME THE FIRST-EVER MYELOMA CLINICAL TRIAL IN FLINT, MICHIGAN, AND IT OPENED AT 25 COMMUNITY HOSPITALS AND CLINICS LAST YEAR. ALSO IN 2025, 13 SITES ENTERED THE START-UP PHASE IN THE HORIZON TWO CLINICAL TRIAL FOCUSED ON HIGH-RISK, NEWLY DIAGNOSED MYELOMA SO THEY COULD FULLY OPEN AND BEGIN SCREENING PATIENTS IN 2026.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$2,669,588ExpenseAmt
Grant$0GrantAmt
Revenue$0RevenueAmt
DescDATA HELPS DRIVE EVERY BREAKTHROUGH IN MYELOMA. BY BUILDING AND SHARING LARGE, HIGH-QUALITY DATASETS, THE MMRF IS CREATING A LAUNCHPAD FOR THE NEXT WAVE OF TREATMENTS, IMPROVEMENTS IN CARE, AND, ULTIMATELY, CURES. IN 2025, THE MMRF LAUNCHED ITS NEXT INNOVATION IN DATA SHARING: THE MMRF VIRTUAL LABTM. VIRTUAL LAB IS NOW MYELOMA'S LARGEST, MOST-COMPREHENSIVE DATA-SHARING PLATFORM AND BRINGS ALL THE MMRF'S DATA INTO ONE PLACE. THE PLATFORM AND ITS ROBUST DATA WILL EMPOWER RESEARCHERS TO ASK BIGGER QUESTIONS, TEST NEW HYPOTHESES, AND ACCELERATE DISCOVERIES THAT IMPROVE OUTCOMES FOR PATIENTS WITH MYELOMA.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$1,600,000ExpenseAmt
Grant$0GrantAmt
Revenue$0RevenueAmt
DescTHE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MYELOMA. IN 2025 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$16,987,283ExpenseAmt
Grant$3,576,906GrantAmt
Revenue$70,864RevenueAmt
DescBEYOND THE PROGRAM EXPENSES OUTLINED ABOVE, THE MMRF ALSO SUPPORTS A RANGE OF STRATEGIC INITIATIVES ALIGNED WITH ITS BROADER MISSION. THIS INCLUDES A ROBUST PORTFOLIO OF CUTTING-EDGE BASIC SCIENCE AND TRANSLATIONAL RESEARCH AIMED AT IDENTIFYING NEW THERAPEUTIC TARGETS THROUGH GENOMICS AND PROTEOMICS; VALIDATION STUDIES TO EXPLORE PROMISING COMPOUNDS AND TREATMENT COMBINATIONS; AND INNOVATIVE CLINICAL TRIALS FOCUSED ON NOVEL AND COMBINATION THERAPIES.FOUNDED BY PATIENTS, THE MMRF IS DEEPLY COMMITTED TO THOSE IMPACTED BY MYELOMA: PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF DISTINGUISHES ITSELF THROUGH ITS BOLD AND COLLABORATIVE APPROACH. WE GENERATE, ANALYZE, AND SHARE THE LARGEST, MOST COMPREHENSIVE SET OF HIGH-QUALITY MYELOMA DATA, MAKING IT PUBLICLY AVAILABLE TO ACCELERATE PROGRESS. BY BRINGING TOGETHER THE RIGHT PEOPLE, PROGRAMS, AND TECHNOLOGIES, THE MMRF IS DRIVING THE RAPID DISCOVERY OF CURES FOR EACH AND EVERY PATIENT.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$16,987,283TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant$3,576,906TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue$70,864TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses$27,353,091TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related InvstYes (1)ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (1)IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (1)ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To IndividualsYes (1)GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent0BusinessRlnWith35CtrlEntInd
Deductible Non Cash ContriYes (1)DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded EntityYes (1)DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document49IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Employee80EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members14GoverningBodyVotingMembersCnt
Independent Voting Member14IndependentVotingMemberCnt
Family Or Business RlnYes (1)FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention PolicyYes (1)DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Other WebsiteYes (X)OtherWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonALAN HEITNERPersonNm
Phone2036520207PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVENUE 7TH FLOORAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (29 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtOfficerOfficerIndKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
KATHY GIUSTI
FOUNDER & DIRECTOR2.00Yes (X)$0$0$0
THOMAS CONHEENEY
CHAIRMAN2.00Yes (X)$0$0$0Yes (X)
GERALD MCDOUGALL
VICE CHAIRMAN2.00Yes (X)$0$0$0Yes (X)
KENNETH ANDERSON MD
DIRECTOR2.00Yes (X)$0$0$0
KAREN ANDREWS
DIRECTOR2.00Yes (X)$0$0$0
RODNEY GILMORE
DIRECTOR2.00Yes (X)$0$0$0
DAVID LUCCHINO
DIRECTOR2.00Yes (X)$0$0$0
LORI TAUBER-MARCUS
DIRECTOR2.00Yes (X)$0$0$0
HUGH MARTIN
DIRECTOR2.00Yes (X)$0$0$0
WILLIAM MCKIERNAN
DIRECTOR2.00Yes (X)$0$0$0
DAVID PARKINSON MD
DIRECTOR2.00Yes (X)$0$0$0
MARIE PINIZZOTTO MD
DIRECTOR THRU 12/31/20252.00Yes (X)$0$0$0
ADRIAN ROSENKRANZ
DIRECTOR2.00Yes (X)$0$0$0
STEVE SHAK MD
DIRECTOR2.00Yes (X)$0$0$0
KIMBERLY WHITE
DIRECTOR2.00Yes (X)$0$0$0
MICHAEL ANDREINI
PRESIDENT & CEO40.00$534,635$0$33,775Yes (X)
ALAN HEITNER
TREASURER & CFO40.00$230,505$0$10,706Yes (X)
KAREN DIETZ
SECRETARY, CAO & GENERAL COUNSEL40.00$287,214$0$48,042Yes (X)
ANNE QUINN YOUNG
CHIEF MISSION OFFICER40.00$374,586$0$19,455Yes (X)
GEORGE MULLIGAN
CHIEF SCIENTIFIC OFFICER40.00$370,521$0$64,920Yes (X)
HEARN CHO
CHIEF MEDICAL OFFICER32.00$227,552$0$9,080Yes (X)
STEPHANIE OESTREICH
MANAGING DIRECTOR, MIF40.00$397,759$0$33,610Yes (X)
KATIE WOZNIAK
VP OF CLINICAL RESEARCH40.00$244,190$0$58,555Yes (X)
PAM SPEER LEWIS
VP OF DEVELOPMENT40.00$224,834$0$19,800Yes (X)
GREG RUBENSTEIN
VP OF MARKETING40.00$220,914$0$61,822Yes (X)
JOANNE PUGLIA
SR DIRECTOR FINANCE, CONTROLLER40.00$199,809$0$12,143Yes (X)
ASHLEY BLANCHARD
SR DIRECTOR, STRATEGIC PARTNERSHIPS40.00$189,544$0$57,601Yes (X)
BRIAN HOCHBERG
PRINCIPAL GIFT OFFICER40.00$184,995$0$55,905Yes (X)
FRANCESCA LAROSA
SR DIRECTOR, HUMAN RESOURCES40.00$183,151$0$26,736Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,870,209TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$512,150TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K41IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
GUSTAVE L LEVY PLACENEW YORKNY10029BIOTECHNOLOGY RESEARCH$3,649,842
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTI
731 ARBOR WAYBLUE BELLPA19422BIOTECHNOLOGY RESEARCH$2,668,810
REDMEDED LLC
5 GREAT VALLEY PARKWAY SUITE 221MALVERNPA19355CONTINUING MEDICAL EDUCATION$1,393,824
RELEVATE HEALTH GROUP LLC
8044 MONTGOMERY ROAD SUITE 700-738CINCINNATIOH45236MARKETING CONSULTANT$950,116
EVEREST CLINICAL RESEARCH CORPORATION
100 SOMERSET CORPORATE BOUELVARDBRIDGEWATERNJ08807BIOTECHNOLOGY RESEARCH$910,373
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K34CntrctRcvdGreaterThan100KCnt
All Other Contributions$26,628,081AllOtherContributionsAmt
Noncash Contributions$625,530NoncashContributionsAmt
Total Contributions$26,628,081TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescRESEARCH & CLINICAL TRIALSDesc
Business541610BusinessCd
Total Revenue Column$8,674,361TotalRevenueColumnAmt
Related Or Exempt Func Income$8,674,361RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$8,674,361TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,162,029TotalRevenueColumnAmt
Exclusion$1,162,029ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$70,864TotalRevenueColumnAmt
Related Or Exempt Func Income$70,864RelatedOrExemptFuncIncomeAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$83,535,069SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$83,547,048SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities-$11,979SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column-$11,979TotalRevenueColumnAmt
Exclusion-$11,979ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$36,523,356TotalRevenueColumnAmt
Related Or Exempt Func Income$8,745,225RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$1,150,050ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$2,171,299TotalAmt
Program Services$2,171,299ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$205,607TotalAmt
Program Services$205,607ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$1,200,000TotalAmt
Program Services$1,200,000ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$3,189,740TotalAmt
Program Services$2,701,103ProgramServicesAmt
Management And General$269,860ManagementAndGeneralAmt
Fundraising$218,777FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$7,259,171TotalAmt
Program Services$4,597,185ProgramServicesAmt
Management And General$616,724ManagementAndGeneralAmt
Fundraising$2,045,262FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$253,502TotalAmt
Program Services$162,762ProgramServicesAmt
Management And General$20,990ManagementAndGeneralAmt
Fundraising$69,750FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$934,672TotalAmt
Program Services$618,576ProgramServicesAmt
Management And General$82,744ManagementAndGeneralAmt
Fundraising$233,352FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$694,531TotalAmt
Program Services$482,213ProgramServicesAmt
Management And General$59,104ManagementAndGeneralAmt
Fundraising$153,214FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$592,317TotalAmt
Program Services$510,934ProgramServicesAmt
Management And General$8,952ManagementAndGeneralAmt
Fundraising$72,431FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$122,586TotalAmt
Program Services$105,743ProgramServicesAmt
Management And General$1,853ManagementAndGeneralAmt
Fundraising$14,990FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$63,798TotalAmt
Program Services$55,032ProgramServicesAmt
Management And General$964ManagementAndGeneralAmt
Fundraising$7,802FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$4,125,819TotalAmt
Program Services$2,401,826ProgramServicesAmt
Management And General$47,616ManagementAndGeneralAmt
Fundraising$1,676,377FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$1,908,430TotalAmt
Program Services$1,618,048ProgramServicesAmt
Management And General$28,844ManagementAndGeneralAmt
Fundraising$261,538FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$1,366,541TotalAmt
Program Services$874,926ProgramServicesAmt
Management And General$2,991ManagementAndGeneralAmt
Fundraising$488,624FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$2,015,355TotalAmt
Program Services$1,738,448ProgramServicesAmt
Management And General$30,460ManagementAndGeneralAmt
Fundraising$246,447FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$179,428TotalAmt
Program Services$154,775ProgramServicesAmt
Management And General$2,712ManagementAndGeneralAmt
Fundraising$21,941FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$668,993TotalAmt
Program Services$465,995ProgramServicesAmt
Management And General$11,855ManagementAndGeneralAmt
Fundraising$191,143FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$852,187TotalAmt
Program Services$474,394ProgramServicesAmt
Fundraising$377,793FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$573,594TotalAmt
Program Services$563,232ProgramServicesAmt
Management And General$2,885ManagementAndGeneralAmt
Fundraising$7,477FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$164,253TotalAmt
Program Services$141,685ProgramServicesAmt
Management And General$2,482ManagementAndGeneralAmt
Fundraising$20,086FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmt
CLINICAL TRIAL/RESEARCH$5,903,326$5,903,326
TISSUE BANKING$205,982$205,982

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$34,651,131TotalAmt
Program Services$27,353,091ProgramServicesAmt
Management And General$1,191,036ManagementAndGeneralAmt
Fundraising$6,107,004FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$253,696TotalAmt
Program Services$126,417ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$127,279FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$2,850,860BOYAmt
EOY$3,561,044EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$6,236,082BOYAmt
EOY$9,961,812EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$4,254,361BOYAmt
EOY$4,884,191EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$1,327,848BOYAmt
EOY$6,305,891EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$487,968BOYAmt
EOY$710,293EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$2,570,033LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$1,896,574LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$2,038,895BOYAmt
EOY$673,459EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$28,979,841BOYAmt
EOY$17,683,741EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$19,702,733BOYAmt
EOY$18,734,641EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$518,560BOYAmt
EOY$357,879EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$66,397,148BOYAmt
EOY$62,872,951EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$11,501,089BOYAmt
EOY$10,559,238EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$2,407,188BOYAmt
EOY$1,374,699EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$1,974,951BOYAmt
EOY$2,575,345EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$491,527BOYAmt
EOY$335,114EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$16,374,755BOYAmt
EOY$14,844,396EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$46,293,816BOYAmt
EOY$44,811,053EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$3,728,577BOYAmt
EOY$3,217,502EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$50,022,393BOYAmt
EOY$48,028,555EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$66,397,148BOYAmt
EOY$62,872,951EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$1,872,225ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$260,157NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets-$4,126,220OtherChangesInNetAssetsAmt
Info In Schedule O Part XIIYes (X)InfoInScheduleOPartXIIInd
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$37,089,868CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$42,022,114CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$30,976,388CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$24,100,727CurrentTaxYearMinus1YearAmt
Current Tax Year$26,628,081CurrentTaxYearAmt
Total$160,817,178TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$37,089,868CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$42,022,114CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$30,976,388CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$24,100,727CurrentTaxYearMinus1YearAmt
Current Tax Year$26,628,081CurrentTaxYearAmt
Total$160,817,178TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$15,201,828SubstantialContributorsTotAmt
Public Support Total170$145,615,350PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$100,955CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$679,638CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,696,550CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,580,287CurrentTaxYearMinus1YearAmt
Current Tax Year$1,162,029CurrentTaxYearAmt
Total$5,219,459TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus3 Years$6,000CurrentTaxYearMinus3YearsAmt
Total$6,000TotalAmt
FieldValueIRS element (for citing)
Total Support$166,042,637TotalSupportAmt
Gross Receipts Rltd Activities$17,483,456GrossReceiptsRltdActivitiesAmt
Public Support CY1700.87700PublicSupportCY170Pct
Public Support PY1700.84980PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:FormAndLineReferenceDesc
ExplanationOTHER INCOME - 2022 AMOUNT: $ 6,000.ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$155,342OtherCostOrOtherBasisAmt
Depreciation$47,793DepreciationAmt
Book Value$107,549BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,414,691OtherCostOrOtherBasisAmt
Depreciation$1,848,781DepreciationAmt
Book Value$565,910BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$673,459TotalBookValueLandBuildingsAmt

Invst Program Related Org InvstProgramRelatedOrgGrp (16 entries)

DescDescBook ValueBookValueAmtMethod ValuationMethodValuationCd
ABCURO, INC.$1,411,251F
INDAPTA THERAPEUTICS$25,000F
FORTIS THERAPEUTIC$500,000F
CYTOIMMUNE THERAPEUTICS$1,999,995F
TRIUMVIRA IMMUNOLOGICS$1,080,222F
TELO THERAPEUTICS$1,155,884F
LUMINARY THERAPEUTICS$1,000,000F
KAHR MEDICAL LTD.$2,666,667F
NECTIN THERAPEUTICS$999,995F
REVERB THERAPEUTICS$1,499,993F
OPNA BIO$1,395,634F
ENVISAGENICS$2,000,000F
NAMMI$500,000F
TRIO$500,000F
UMOJA$1,000,000F
STYLUS MEDICAINE$1,000,000F
FieldValueIRS element (for citing)
Total Book Value Program Rltd$18,734,641TotalBookValueProgramRltdAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescOPERATING LEASE LIABILITYDesc
Amt$335,114Amt
FieldValueIRS element (for citing)
Total Liability$335,114TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$35,557,739TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$260,157NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$694,778DonatedServicesAndUseFcltsAmt
Revenue Not Reported$954,935RevenueNotReportedAmt
Revenue Subtotal$34,602,804RevenueSubtotalAmt
Other Revenues Not Included$1,920,552OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$1,920,552RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$36,523,356TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$32,608,298TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$694,778DonatedServicesUseFcltsAmt
Expenses Not Reported$694,778ExpensesNotReportedAmt
Expenses Subtotal$31,913,520ExpensesSubtotalAmt
Other Expenses Not Included$2,737,611OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt$2,737,611ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$34,651,131TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART X, LINE 2:THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE.
PART XI, LINE 4B - OTHER ADJUSTMENTS:SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,920,552.
PART XII, LINE 4B - OTHER ADJUSTMENTS:SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,920,552. RETURN OF UNSPENT GRANT FUNDS 817,059.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA00GRANTMAKING$60,000
EUROPE (INCLUDING ICELAND & GREENLAND)00GRANTMAKING$1,110,000
MIDDLE EAST AND NORTH AFRICA00INVESTMENTS$3,666,662
EUROPE (INCLUDING ICELAND & GREENLAND)00INVESTMENTS$1,395,634
NORTH AMERICA00INVESTMENTS$1,499,993
SUB-SAHARAN AFRICA00GRANTMAKING$30,000
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees0SubtotalEmployeesCnt
Continuation Total Office0ContinuationTotalOfficeCnt
Continuation Total Employee0ContinuationTotalEmployeeCnt
Total Office0TotalOfficeCnt
Total Employee0TotalEmployeeCnt
Subtotal Spent$7,762,289SubtotalSpentAmt
Continuation Spent$0ContinuationSpentAmt
Total Spent$7,762,289TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (4 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtNon Cash AssistanceNonCashAssistanceAmt
EUROPE (INCLUDING ICELAND & GREENLAND)MAC GRANT$1,050,000WIRE$0
SUB-SAHARAN AFRICAFELLOWS$30,000WIRE$0
NORTH AMERICAFELLOWS$60,000WIRE$0
EUROPE (INCLUDING ICELAND & GREENLAND)FELLOWS$60,000WIRE$0
FieldValueIRS element (for citing)
Total501c3 Org4Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt
Transfer To Foreign CorpYes (1)TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp OwnershipYes (1)ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 2:MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE.
SCHEDULE F, PART IV, LINE 1:THE ORGANIZATION IS REQUIRED TO FILE FORM 926 AS IT MEETS THE APPLICABLE FILING REQUIREMENT THRESHOLDS.
SCHEDULE F, PART IV, LINE 3:THE ORGANIZATION IS NOT REQUIRED TO FILE FORM 5471 AS DOES NOT MEET THE APPLICABLE FILING REQUIREMENT THRESHOLDS OR OWNERSHIP AMOUNT.

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (8 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtNon Cash AssistanceNonCashAssistanceAmtPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE
1450 EAST DUARTE ROADDUARTECA91010953432210501(C)(3)$171,210$0SITE INVESTMENT GRANT
BETH ISREAL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUEBOSTONMA02215042103881501(C)(3)$136,418$0FELLOW, SITE INVESTMENT GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE PO BOXNEW YORKNY10029136171197501(C)(3)$1,150,000$0SITE INVESTMENT GRANT, MAC GRANT1075
INDIANA UNIVERSITY
400 E 7TH STREET POPLARS 501BLOOMINGTONIN47405356001673501(C)(3)$60,000$0FELLOW
TRUSTEES OF BOSTON UNIVERSITY
881 COMMONWEALTH AVEBOSTONMA02215042103547501(C)(3)$35,989$0SCHOLARS
UNIVERSITY OF MIAMI
PO BOX 248106CORAL GABLESFL33124590624458501(C)(3)$30,000$0FELLOW
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
7007 BERTNER AVENUE SUITE 182457HOUSTONTX77030760300816501(C)(3)$426,025$0VLAB PROJECTS
WASHINGTON UNIVERSITY IN ST LOUIS
660 EAST EUCLID AVENUEST LOUISMO63110430653611501(C)(3)$157,300$0SITE INVESTMENT GRANT
FieldValueIRS element (for citing)
Total501c3 Org8Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp

FieldValueIRS element (for citing)
Grant TypeFELLOWSHIP AWARDSGrantTypeTxt
Recipient9RecipientCnt
Cash Grant$205,607CashGrantAmt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 2:FormAndLineReferenceDesc
ExplanationGRANT MONITORING PROCEDURES THE MMRF MAINTAINS A FORMAL REVIEW, APPROVAL, AND MONITORING PROCESS FOR RESEARCH GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT AWARDS. RESEARCH BUDGET APPROVAL AND OVERSIGHT THE ANNUAL RESEARCH BUDGET IS INITIALLY REVIEWED AND APPROVED BY THE PROGRAMMING COMMITTEE. FOLLOWING PROGRAMMING COMMITTEE APPROVAL, THE BUDGET IS PRESENTED TO THE MMRF BOARD OF DIRECTORS FOR FINAL APPROVAL. RESEARCH AWARD ACTIVITY AND BUDGET PERFORMANCE ARE MONITORED ON AN ONGOING BASIS THROUGH MONTHLY RESEARCH PROGRAMMATIC MEETINGS WITH THE CEO AND CFO. THESE MEETINGS PROVIDE OVERSIGHT OF THE DISTRIBUTION AND MANAGEMENT OF RESEARCH AWARDS AND SERVE AS A FORUM TO REVIEW BUDGET UPDATES, CHANGES, AND REFORECASTS. ANY MATERIAL BUDGETARY CHANGE OR REFORECAST IN EXCESS OF $1 MILLION IS ESCALATED TO THE PROGRAMMING COMMITTEE FOR REVIEW AND DISCUSSION. THE MMRF AWARDS TWO PRIMARY TYPES OF GRANTS: CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. CLASSICAL RESEARCH SUPPORT GRANTS CLASSICAL RESEARCH GRANT PROPOSALS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE SUBJECT-MATTER EXPERTISE. SCIENTIFIC MERIT IS EVALUATED USING THE CURRENT NIH SCORING SYSTEM, WITH SCORES RANGING FROM 1 TO 9, WHERE 1 REPRESENTS THE HIGHEST SCIENTIFIC MERIT AND 9 REPRESENTS THE LOWEST. EACH PROPOSAL IS REVIEWED BY TWO INDEPENDENT EXTERNAL REVIEWERS, AND THE SCORES ARE AVERAGED. GRANTS SELECTED FOR FUNDING GENERALLY RECEIVE AN AVERAGE SCORE OF 3 OR BETTER. AFTER EXTERNAL SCIENTIFIC REVIEW IS COMPLETED, MMRF RESEARCH LEADERSHIP PERFORMS A FINAL REVIEW OF THE PROPOSALS AND MAKES FUNDING RECOMMENDATIONS TO THE CEO AND CFO FOR CONFIRMATION OF THE FINAL AWARDS. ONCE A GRANT AWARD IS APPROVED, AN AWARD LETTER IS ISSUED TO THE RECIPIENT, AND THE CFO IS NOTIFIED SO THAT THE APPROPRIATE GRANT ACCRUAL CAN BE RECORDED. GRANT PAYMENTS ARE SUBJECT TO CONTINUED MONITORING. AFTER THE INITIAL PAYMENT, THE INVESTIGATOR IS REQUIRED TO SUBMIT PROGRESS REPORTS IN ORDER TO RECEIVE SUBSEQUENT PAYMENTS. THESE PROGRESS REPORTS ARE REVIEWED BY EXTERNAL REVIEWERS TO DETERMINE WHETHER APPROPRIATE PROGRESS HAS BEEN MADE AND WHETHER THE FINDINGS SUPPORT CONTINUED FUNDING OF THE STUDY. ONCE THE RESEARCH EMPLOYEE RESPONSIBLE FOR GRANT COORDINATION RECEIVES CONFIRMATION THAT SUFFICIENT PROGRESS HAS BEEN MADE, THE PROGRESS AND FINDINGS ARE PRESENTED TO AN APPROVAL COMMITTEE FOR AUTHORIZATION OF THE NEXT FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS CLINICAL AND TRANSLATIONAL SITE SUPPORT GRANT PROPOSALS ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP, IN COLLABORATION WITH OUTSIDE ADVISORS AS APPROPRIATE. MMRF RESEARCH LEADERSHIP THEN MAKES FUNDING RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. ONCE A CLINICAL OR TRANSLATIONAL SITE SUPPORT GRANT IS APPROVED, AN AWARD LETTER IS ISSUED TO THE RECIPIENT, AND THE CFO IS NOTIFIED SO THAT THE APPROPRIATE GRANT ACCRUAL CAN BE RECORDED. THESE GRANTS ARE TYPICALLY RENEWED ANNUALLY OR STRUCTURED AS MULTI-YEAR AWARDS. CONTINUATION OR RENEWAL OF FUNDING IS BASED ON THE ACHIEVEMENT OF MILESTONES ESTABLISHED AT THE INCEPTION OF THE PROGRAM. THE MMRF ALSO MAINTAINS A CONFLICT-OF-INTEREST POLICY. ANY POTENTIAL CONFLICTS OR RELATED ISSUES ARISING IN CONNECTION WITH GRANT AWARDS ARE REVIEWED BY THE APPROPRIATE COMMITTEE.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (1)AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
MICHAEL ANDREINI
PRESIDENT & CEO$404,078$0$130,185$0$372$0$14,000$0$19,775$0$568,410$0$0$0
GEORGE MULLIGAN
CHIEF SCIENTIFIC OFFICER$281,776$0$62,620$0$26,125$0$14,000$0$50,920$0$435,441$0$0$0
STEPHANIE OESTREICH
MANAGING DIRECTOR, MIF$322,532$0$65,400$0$9,827$0$14,000$0$19,610$0$431,369$0$0$0
ANNE QUINN YOUNG
CHIEF MISSION OFFICER$279,668$0$66,198$0$28,720$0$14,000$0$5,455$0$394,041$0$0$0
KAREN DIETZ
SECRETARY, CAO & GENERAL COUNSEL$208,201$0$53,416$0$25,597$0$12,140$0$35,902$0$335,256$0$0$0
KATIE WOZNIAK
VP OF CLINICAL RESEARCH$207,797$0$23,903$0$12,490$0$7,725$0$50,830$0$302,745$0$0$0
GREG RUBENSTEIN
VP OF MARKETING$181,866$0$20,910$0$18,138$0$9,702$0$52,120$0$282,736$0$0$0
ASHLEY BLANCHARD
SR DIRECTOR, STRATEGIC PARTNERSHIPS$161,179$0$14,438$0$13,927$0$8,102$0$49,499$0$247,145$0$0$0
PAM SPEER LEWIS
VP OF DEVELOPMENT$195,905$0$15,000$0$13,929$0$0$0$19,800$0$244,634$0$0$0
ALAN HEITNER
TREASURER & CFO$215,412$0$0$0$15,093$0$9,200$0$1,506$0$241,211$0$0$0
BRIAN HOCHBERG
PRINCIPAL GIFT OFFICER$162,899$0$13,500$0$8,596$0$7,902$0$48,003$0$240,900$0$0$0
HEARN CHO
CHIEF MEDICAL OFFICER$170,953$0$39,952$0$16,647$0$9,080$0$0$0$236,632$0$0$0
JOANNE PUGLIA
SR DIRECTOR FINANCE, CONTROLLER$167,694$0$13,770$0$18,345$0$8,060$0$4,083$0$211,952$0$0$0
FRANCESCA LAROSA
SR DIRECTOR, HUMAN RESOURCES$156,365$0$12,698$0$14,088$0$7,432$0$19,304$0$209,887$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 7FormAndLineReferenceDesc
ExplanationINDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2025, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2025 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution34ContributionCnt
Noncash Contributions Rpt F990$625,530NoncashContributionsRptF990Amt
Method Of Determining RevenuesAVG. SELLING PRICEMethodOfDeterminingRevenuesTxt
FieldValueIRS element (for citing)
Form8283 Received0Form8283ReceivedCnt
Any Property That Must Be Held0AnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (1)ReviewProcessUnusualNCGiftsInd
Third Parties Used0ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, COLUMN (B):FormAndLineReferenceDesc
ExplanationTHE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (10 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART I, LINE 1:MMRF ACCOMPLISHMENTS FOR 2025 THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AND ITS WHOLLY OWNED SUBSIDIARIES, THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC ("MMRC") AND MYELOMA INVESTMENT FUND, LLC ("MIF"), COLLECTIVELY REFERRED TO AS "THE MMRF," IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. THE MMRF DRIVES THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGES DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES, AND EMPOWERS MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO THE MMRF'S MISSION IS ITS COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES THEY PURSUE. SINCE ITS INCORPORATION ON JANUARY 13, 1998, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, SUPPORTED NEARLY 100 CLINICAL TRIALS AND RESEARCH STUDIES, AND HELPED BRING OVER 15 FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. IN 2025, THE MMRF INVESTED $27.1M IN CRITICAL RESEARCH PROGRAMS AND PATIENT EDUCATION PROGRAMS FOR MYELOMA PATIENTS. THROUGH THE MYELOMA INVESTMENT FUND (MIF), WE INVESTED IN TWO NEW EARLY STAGE BIOTECH COMPANIES PURSUING INNOVATIVE, POTENTIALLY GAME-CHANGING TREATMENTS FOR MYELOMA. THE HORIZON CLINICAL TRIALS PROGRAMRUN BY THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC)MEANINGFULLY ADVANCED. THE HORIZON ONE TRIAL, FOCUSED ON RELAPSED/REFRACTORY MYELOMA, SURPASSED MANY OF ITS ENROLLMENT GOALS. HORIZON TWO BEGAN, FOCUSED ON HIGH-RISK, NEWLY DIAGNOSED PATIENTS, BEGAN ACTIVATING SITES AT THE END OF 2025.
FORM 990, PART III, LINE 1:THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. WE DRIVE THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGE DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES, AND EMPOWER MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO OUR MISSION IS OUR COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES WE PURSUE. SINCE OUR INCEPTION, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, SUPPORTED NEARLY 100 CLINICAL TRIALS AND RESEARCH STUDIES, AND HELPED BRING OVER 15 FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS.
FORM 990, PART VI, SECTION A, LINE 2KATHY GIUSTI, FOUNDER & FORMER CHIEF MISSION OFFICER, AND KAREN ANDREWS, BOARD MEMBER HAVE A FAMILY RELATIONSHIP.
FORM 990, PART VI, SECTION B, LINE 11BTHE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS.
FORM 990, PART VI, SECTION B, LINE 12CTHE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO ANY DIRECTOR, OFFICER, OR MEMBER OF A STANDING OR ADVISORY COMMITTEE WITH POWERS DELEGATED BY THE MMRF BOARD OF DIRECTORS WHO MAY HAVE A DIRECT OR INDIRECT FINANCIAL INTEREST (I.E. "INTERESTED PERSON"). DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR AUDIT COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE AUDIT COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR AUDIT COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR AUDIT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR AUDIT COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE AUDIT COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE AUDIT COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR AUDIT COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR AUDIT COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS. COMPENSATION IS BENCHMARKED AGAINST OTHER 501(C)(3)'S, RESEARCH ORGANIZATIONS, THIRD PARTY COMPENSATION DATABASE AND THEN REVIEWED BY THE AUDIT AND FINANCE COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2025.
FORM 990, PART VI, SECTION C, LINE 19FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES.
FORM 990, PART IX, LINE 11GCONSULTING: PROGRAM SERVICE EXPENSES 1,053,065. MANAGEMENT AND GENERAL EXPENSES 25,938. FUNDRAISING EXPENSES 1,433,745. TOTAL EXPENSES 2,512,748. MEDICAL PROFESSIONALS: PROGRAM SERVICE EXPENSES 1,167,026. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 185,889. TOTAL EXPENSES 1,352,915. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 181,735. MANAGEMENT AND GENERAL EXPENSES 21,678. FUNDRAISING EXPENSES 56,743. TOTAL EXPENSES 260,156.
FORM 990, PART XI, LINE 9:LOSS ON DISPOSAL OF ASSETS -1,590,337. IMPAIRMENT ON PROGRAMMATIC INVESTMENTS -3,352,942. RETURN OF UNSPENT GRANT FUNDS 817,059.
FORM 990, PART XII, LINE 2C:THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdTotal IncomeTotalIncomeAmtEnd Of Year AssetsEndOfYearAssetsAmtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Txt
MYELOMA INVESTMENT FUND LLC
383 MAIN AVENUE 5TH FLOORNORWALKCT06851471162865VENTURE PHILANTHROPY FUNDDE$5,119,292$20,434,115THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC
383 MAIN AVENUE 5TH FLOORNORWALKCT06851471142650FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCHCT$7,955,376$6,932,627THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.